Related Experiment Video

Updated: May 27, 2026

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

Stratifying risk factors for multidrug-resistant pathogens in hospitalized patients coming from the community with

Stefano Aliberti1, Marta Di Pasquale, Anna Maria Zanaboni

  • 1Dipartimento di Medicina Clinica e Prevenzione, University of Milan-Bicocca, Clinica Pneumologica, AO San Gerardo, Monza, Italy. stefano.aliberti@unimib.it

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|November 24, 2011
PubMed
Abstract

Insights

Recent hospitalization and nursing home residency are key predictors of multidrug-resistant (MDR) bacterial pneumonia in community-acquired cases. A weighted approach is needed to identify resistant pathogens effectively.

Area of Science:

  • Infectious Diseases
  • Epidemiology
  • Clinical Medicine

Background:

  • Not all risk factors equally predict multidrug-resistant (MDR) organisms in community-acquired pneumonia.
  • Evaluating specific risk factors for MDR bacteria acquisition in hospitalized pneumonia patients is crucial.
  • Study focused on actual infection and clinical outcomes during hospitalization.

Purpose of the Study:

  • To evaluate risk factors for acquiring MDR bacteria in community-acquired pneumonia patients.
  • To identify independent predictors of resistant pathogen infection and in-hospital mortality.
  • To develop a predictive score for pneumonia caused by resistant pathogens.

Main Methods:

  • Prospective observational study of consecutive community-acquired pneumonia patients.
  • Data collection on admission and during hospitalization.
  • Logistic regression models to assess independent risk factors and mortality predictors.

Main Results:

  • 51% of 935 patients had at least one MDR risk factor on admission.
  • Hospitalization within 90 days (OR 4.87) and nursing home residency (OR 3.55) independently predicted resistant infections.
  • These factors also independently predicted in-hospital mortality.

Conclusions:

  • Risk factors for MDR acquisition require differential weighting.
  • A probabilistic approach is recommended for identifying resistant pathogens in community-acquired pneumonia.
  • Findings support a more nuanced risk assessment for MDR infections.

More Related Videos

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii09:17

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

Published on: January 2, 2017

Related Concept Videos

Pneumonia I: Introduction01:29

Pneumonia I: Introduction

Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
Mechanism of Antibiotic Resistance in MRSA01:25

Mechanism of Antibiotic Resistance in MRSA

Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...